{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:42Z","timestamp":1792202382458,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,8,1]],"date-time":"2002-08-01T00:00:00Z","timestamp":1028160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2002,8]]},"DOI":"10.1124\/dmd.30.8.883","type":"journal-article","created":{"date-parts":[[2003,1,15]],"date-time":"2003-01-15T18:17:35Z","timestamp":1042654655000},"page":"883-891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":392,"title":["Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7"],"prefix":"10.1016","volume":"30","author":[{"given":"J.Andrew","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varon E.","family":"Cantrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Ruterbories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell A.","family":"Hamman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Wrighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.30.8.883_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1021\/tx0002132","article-title":"Allosteric behavior in cytochrome p450-dependent in vitro drug-drug interactions: a prospective based on conformational dynamics.","volume":"14","author":"Atkins","year":"2001","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.30.8.883_bib2","unstructured":"Benet LZ (1996) Pharmacokinetics Goodman and Gilman's: The Pharmacological Basis of Therapeutics (Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG ed) pp 14 McGraw-Hill, New York."},{"key":"10.1124\/dmd.30.8.883_bib3","unstructured":"Copeland RA (1996) Enzyme Kinetics. Wiley-VCH Inc., New York."},{"key":"10.1124\/dmd.30.8.883_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0026-895X(24)12850-7","article-title":"cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.","volume":"59","author":"Domanski","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.30.8.883_bib5","doi-asserted-by":"crossref","first-page":"10150","DOI":"10.1021\/bi010758a","article-title":"Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity.","volume":"40","author":"Domanski","year":"2001","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.30.8.883_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/PL00004948","article-title":"Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.","volume":"355","author":"Evert","year":"1997","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"10.1124\/dmd.30.8.883_bib7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00008571-200103000-00002","article-title":"Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene.","volume":"11","author":"Gellner","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.30.8.883_bib8","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1006\/abbi.1995.1177","article-title":"Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5\u2032 modification, purification, spectral characterization, reconstitution conditions and catalytic activities.","volume":"317","author":"Gillam","year":"1995","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.30.8.883_bib9","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1006\/abbi.1997.0286","article-title":"Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5\u2032 modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase.","volume":"346","author":"Gillam","year":"1997","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.30.8.883_bib10","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.30.8.883_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/004982599238173","article-title":"Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily.","volume":"29","author":"Gorski","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.30.8.883_bib12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model.","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.8.883_bib13","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0022-3565(24)35013-X","article-title":"Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.","volume":"290","author":"Jones","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.30.8.883_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2125.1999.00073.x","article-title":"CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.","volume":"48","author":"Kenworthy","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.30.8.883_bib15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0009-9236(98)90055-8","article-title":"Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.","volume":"64","author":"Kivisto","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.30.8.883_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0006-2952(96)00836-2","article-title":"Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4.","volume":"53","author":"Koley","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.30.8.883_bib17","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1021\/bi9715627","article-title":"Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.","volume":"37","author":"Korzekwa","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.30.8.883_bib18","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.30.8.883_bib19","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0022-3565(24)29399-X","article-title":"Characterization of the NADPH-dependent metabolism of 17 beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5.","volume":"298","author":"Lee","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.30.8.883_bib20","first-page":"137","article-title":"Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.","volume":"8","author":"Maenpaa","year":"1998","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.30.8.883_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00008571-199602000-00002","article-title":"P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.","volume":"6","author":"Nelson","year":"1996","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.30.8.883_bib22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0090-9556(25)08382-5","article-title":"In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.","volume":"22","author":"Ring","year":"1994","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.8.883_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1006\/abio.1999.4775","volume":"286","author":"Satoh","year":"2000","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.30.8.883_bib24","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0026-895X(24)12050-0","article-title":"Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+).","volume":"28","author":"Schrag","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.8.883_bib25","first-page":"70","article-title":"Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.","volume":"29","author":"Schrag","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.8.883_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00008571-199402000-00002","article-title":"Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver.","volume":"4","author":"Schuetz","year":"1994","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.30.8.883_bib27","unstructured":"Segel IH (1975) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems. John Wiley & Sons Inc., New York."},{"key":"10.1124\/dmd.30.8.883_bib28","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0090-9556(24)13672-0","article-title":"Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.","volume":"28","author":"Stresser","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.30.8.883_bib29","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0022-3565(24)35211-5","article-title":"Interaction of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism.","volume":"291","author":"Tang","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.30.8.883_bib30","first-page":"4667","article-title":"Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer.","volume":"60","author":"Williams","year":"2000","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.30.8.883_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0026-895X(25)09441-6","article-title":"Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).","volume":"38","author":"Wrighton","year":"1990","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.30.8.883_bib32","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0026-895X(25)09114-X","article-title":"Identification of a polymorphically expressed member of the human cytochrome P-450III family.","volume":"36","author":"Wrighton","year":"1989","journal-title":"Mol Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624044842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624044842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.30.8.883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T13:17:08Z","timestamp":1739884628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624044842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["S0090955624044842"],"URL":"https:\/\/doi.org\/10.1124\/dmd.30.8.883","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2002,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Metabolic Capabilities of CYP3A4, CYP3A5, and CYP3A7","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.30.8.883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2002 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}